Inhibition of basal insulin secretion induces insulin resistance in normal man: evidence for a tonic effect of insulin on carbohydrate metabolism. 1989

A Bertoli, and S Caputo, and M A Marini, and S A Santini, and G Ghirlanda, and A V Greco
Istituto di Clinica Medica, Università Cattolica SC, Roma, Italia.

Insulin resistance has been demonstrated both in insulin deficiency and insulin excess in man and in animals. This study was carried out in normal man to evaluate the role of insulinopenia in the pathogenesis of insulin resistance. Insulin suppression was obtained by 4 h somatostatin (SRIF) infusion. Insulin receptors on circulating monocytes were evaluated before and after SRIF infusion; an insulin tolerance test (ITT) was performed after SRIF, saline or SRIF and replacing basal insulin secretion. Insulin binding to circulating monocytes did not change after 4 h insulinopenia (2.19 +/- 0.30 vs. 2.35 +/- 0.80%), while insulin sensitivity appeared decreased after SRIF (KITT = 0.97 +/- 0.13) as compared with saline (KITT = 3.30 +/- 0.42), and this effect was prevented by insulin (KITT = 2.46 +/- 0.38). A relationship was detected between KITT and plasma insulin concentration before ITT (r = 0.85, p less than 0.01), suggesting that insulin deficiency is the main cause of the phenomenon observed. The present data suggest that basal insulin concentration plays an essential role in the control of insulin sensitivity. If insulin binding on monocytes mimics the behavior of major insulin target tissues, it is possible that the impaired insulin action after 4 h of insulin deficiency is related to a post binding effect.

UI MeSH Term Description Entries
D007328 Insulin A 51-amino acid pancreatic hormone that plays a major role in the regulation of glucose metabolism, directly by suppressing endogenous glucose production (GLYCOGENOLYSIS; GLUCONEOGENESIS) and indirectly by suppressing GLUCAGON secretion and LIPOLYSIS. Native insulin is a globular protein comprised of a zinc-coordinated hexamer. Each insulin monomer containing two chains, A (21 residues) and B (30 residues), linked by two disulfide bonds. Insulin is used as a drug to control insulin-dependent diabetes mellitus (DIABETES MELLITUS, TYPE 1). Iletin,Insulin A Chain,Insulin B Chain,Insulin, Regular,Novolin,Sodium Insulin,Soluble Insulin,Chain, Insulin B,Insulin, Sodium,Insulin, Soluble,Regular Insulin
D007333 Insulin Resistance Diminished effectiveness of INSULIN in lowering blood sugar levels: requiring the use of 200 units or more of insulin per day to prevent HYPERGLYCEMIA or KETOSIS. Insulin Sensitivity,Resistance, Insulin,Sensitivity, Insulin
D007457 Iodine Radioisotopes Unstable isotopes of iodine that decay or disintegrate emitting radiation. I atoms with atomic weights 117-139, except I 127, are radioactive iodine isotopes. Radioisotopes, Iodine
D008297 Male Males
D001786 Blood Glucose Glucose in blood. Blood Sugar,Glucose, Blood,Sugar, Blood
D004032 Diet Regular course of eating and drinking adopted by a person or animal. Diets
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000078790 Insulin Secretion Production and release of insulin from PANCREATIC BETA CELLS that primarily occurs in response to elevated BLOOD GLUCOSE levels. Secretion, Insulin
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D013004 Somatostatin A 14-amino acid peptide named for its ability to inhibit pituitary GROWTH HORMONE release, also called somatotropin release-inhibiting factor. It is expressed in the central and peripheral nervous systems, the gut, and other organs. SRIF can also inhibit the release of THYROID-STIMULATING HORMONE; PROLACTIN; INSULIN; and GLUCAGON besides acting as a neurotransmitter and neuromodulator. In a number of species including humans, there is an additional form of somatostatin, SRIF-28 with a 14-amino acid extension at the N-terminal. Cyclic Somatostatin,Somatostatin-14,Somatotropin Release-Inhibiting Hormone,SRIH-14,Somatofalk,Somatostatin, Cyclic,Somatotropin Release-Inhibiting Factor,Stilamin,Somatostatin 14,Somatotropin Release Inhibiting Factor,Somatotropin Release Inhibiting Hormone

Related Publications

A Bertoli, and S Caputo, and M A Marini, and S A Santini, and G Ghirlanda, and A V Greco
January 1988, International journal of clinical pharmacology, therapy, and toxicology,
A Bertoli, and S Caputo, and M A Marini, and S A Santini, and G Ghirlanda, and A V Greco
November 1970, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme,
A Bertoli, and S Caputo, and M A Marini, and S A Santini, and G Ghirlanda, and A V Greco
April 1978, Diabetologia,
A Bertoli, and S Caputo, and M A Marini, and S A Santini, and G Ghirlanda, and A V Greco
January 1953, Archivio "E. Maragliano" di patologia e clinica,
A Bertoli, and S Caputo, and M A Marini, and S A Santini, and G Ghirlanda, and A V Greco
January 1987, European journal of clinical pharmacology,
A Bertoli, and S Caputo, and M A Marini, and S A Santini, and G Ghirlanda, and A V Greco
July 1975, Acta endocrinologica,
A Bertoli, and S Caputo, and M A Marini, and S A Santini, and G Ghirlanda, and A V Greco
June 1973, The Journal of clinical investigation,
A Bertoli, and S Caputo, and M A Marini, and S A Santini, and G Ghirlanda, and A V Greco
June 1983, Metabolism: clinical and experimental,
A Bertoli, and S Caputo, and M A Marini, and S A Santini, and G Ghirlanda, and A V Greco
July 1971, Journal of applied physiology,
A Bertoli, and S Caputo, and M A Marini, and S A Santini, and G Ghirlanda, and A V Greco
October 1969, Neurology,
Copied contents to your clipboard!